Status:
RECRUITING
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
Lead Sponsor:
Eli Lilly and Company
Conditions:
Healthy
Overweight
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
The main purpose of this study is to evaluate the safety, tolerability of LY4086940 and how it is processed in the body. Participation in Part A of the study will last about 10 weeks and may include ...
Eligibility Criteria
Inclusion
- Have no significant body weight change for the 3 months prior to screening
- Part A and Part E:
- Are considered healthy
- Have a body mass index (BMI) of 22 to 35 kilograms per square meter (kg/m2) at screening
- Part B:
- Have a BMI of 27 to 45 kg/m2 at screening
- Part C:
- Have a BMI of 25 to 45 kg/m2 at screening
- Part D:
- Have type 2 diabetes
- Have hemoglobin A1C (HbA1c) ≥7.0% and ≤10.5% at screening
- Have a BMI of 27 to 45 kg/m2 at screening
Exclusion
- Have had an acute cardiovascular condition within the past 6 months prior to screening
- Have liver disease or pancreatitis
- Have used medications for weight loss within the 3 months prior to screening
- Parts A, B, C, E:
- Have any form of diabetes
- Part D:
- Have type 1 diabetes
Key Trial Info
Start Date :
April 23 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2026
Estimated Enrollment :
201 Patients enrolled
Trial Details
Trial ID
NCT06945419
Start Date
April 23 2025
End Date
April 1 2026
Last Update
December 24 2025
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Fortrea Clinical Research Unit
Daytona Beach, Florida, United States, 32117
2
Fortrea Clinical Research Unit
Dallas, Texas, United States, 75247
3
Endeavor Clinical Trials
San Antonio, Texas, United States, 78240
4
Lilly Centre for Clinical Pharmacology
Singapore, Singapore, 138623